Literature DB >> 18056853

Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations.

Mariam Azarian, Marc Busson, Virginia Lepage, Dominique Charron, Antoine Toubert, Pascale Loiseau, Regis Peffault de Latour, Vanderson Rocha, Gerard Socié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18056853     DOI： 10.1182/blood-2007-08-106385

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

Review 1.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

2.  Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis.

Authors:  Salyka Sengsayadeth; Tao Wang; Stephanie J Lee; Michael D Haagenson; Stephen Spellman; Marcelo A Fernandez Viña; Carlheinz R Muller; Michael R Verneris; Bipin N Savani; Madan Jagasia
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-14       Impact factor: 5.742

3.  Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients.

Authors:  Mahdiyar Iravani Saadi; Ramin Yaghobi; Mohammad Hossein Karimi; Bita Geramizadeh; Mani Ramzi; Maryam Zakerinia
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

Review 4.  Clinical applications for biomarkers of acute and chronic graft-versus-host disease.

Authors:  John E Levine; Sophie Paczesny; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

Review 5.  Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.

Authors:  John A Hansen; Jason W Chien; Edus H Warren; Lue Ping Zhao; Paul J Martin
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

6.  Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Authors:  Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

Review 7.  Immune tolerance induction by integrating innate and adaptive immune regulators.

Authors:  Jun Suzuki; Camillo Ricordi; Zhibin Chen
Journal:  Cell Transplant       Date:  2009-11-16       Impact factor: 4.064

8.  Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes.

Authors:  Peter T Jindra; Susan E Conway; Stacy M Ricklefs; Stephen F Porcella; Sarah L Anzick; Mike Haagenson; Tao Wang; Stephen Spellman; Edgar Milford; Peter Kraft; David H McDermott; Reza Abdi
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-05       Impact factor: 5.742

Review 9.  Role of non-HLA gene polymorphisms in graft-versus-host disease.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2013-08-15       Impact factor: 2.490

10.  Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia.

Authors:  Sandro Orrù; Nicola Orrù; Emmanouil Manolakos; Roberto Littera; Giovanni Caocci; Giovanna Giorgiani; Alice Bertaina; Daria Pagliara; Claudio Giardini; Sonia Nesci; Franco Locatelli; Carlo Carcassi; Giorgio La Nasa
Journal:  Hum Immunol       Date:  2011-12-31       Impact factor: 2.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.